PARATEK PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 268
- Market Cap
- -
- Website
- http://www.paratekpharma.com
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections
- Conditions
- Bacterial Infections
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 40
- Registration Number
- NCT05217537
- Locations
- 🇺🇸
Site 109, Little Rock, Arkansas, United States
🇺🇸Site 112, Long Beach, California, United States
🇺🇸Site 107, Orange, California, United States
Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
- Conditions
- Mycobacterium Infections, NontuberculousNontuberculous Mycobacterial Pulmonary InfectionMycobacterium Abscessus InfectionNontuberculous Mycobacterial Lung Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 66
- Registration Number
- NCT04922554
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸St. Francis Medical Institute, Clearwater, Florida, United States
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
- Conditions
- Community-acquired PneumoniaBacterial Pneumonia
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 670
- Registration Number
- NCT04779242
- Locations
- 🇧🇬
Site 210, Gabrovo, Bulgaria
🇧🇬Site 213, Lom, Bulgaria
🇧🇬Site 208, Pernik, Bulgaria
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 18
- Registration Number
- NCT04160260
- Locations
- 🇺🇸
Site 105, Birmingham, Alabama, United States
🇺🇸Site 102, San Diego, California, United States
🇺🇸Site 104, San Diego, California, United States
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 201
- Registration Number
- NCT03757234
- Locations
- 🇬🇪
Site 201, Tbilisi, Georgia
🇬🇪Site 202, Tbilisi, Georgia
🇬🇪Site 203, Tbilisi, Georgia
- Prev
- 1
- 2
- 3
- Next